London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections

blonca9
Nov 22, 2024
1 min read

CEO Francesco Maria Lavino describes the unmet need in this area and the science behind how F2G combats it. Plus, learnings from an FDA CRL the current development and regulatory plan.

Recent Posts

See All

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

BIO International 2025: Sweden's Alligator has a phase three ready CD40 asset for pancreatic cancer and is looking for a partner to move it forward

London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight